Morgan Stanley analyst Judah Frommer initiates coverage on Avalyn Pharma (NASDAQ: AVLN) with a Overweight rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage